curacle co., ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 34
- Market Cap
- -
- Website
- http://www.curacle.com
Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Curacle Co., Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT05907330
Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Curacle Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT05718375
- Locations
- 🇰🇷
Yeongnam University Medical Center, Daegu, Korea, Republic of
The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME)
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Curacle Co., Ltd.
- Target Recruit Count
- 67
- Registration Number
- NCT05573100
- Locations
- 🇵🇷
Emanuelli Research & Development Center, Arecibo, Puerto Rico
🇺🇸Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
🇺🇸Wagner Macula and Retina Center, Norfolk, Virginia, United States
First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers
Phase 1
Completed
- Conditions
- Diabetic Macular Edema
- Interventions
- Drug: PlaceboDrug: CU06-1004, Multiple dosesDrug: CU06-1004, Single dose
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- Curacle Co., Ltd.
- Target Recruit Count
- 81
- Registration Number
- NCT04795037
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
© Copyright 2025. All Rights Reserved by MedPath